Sugi Predict

Sugi Predict / Compounds / SCHEMBL30565192

SCHEMBL30565192

SCHEMBL30565192

CC(C)(C)OC(=O)N[C@@H](CCCNC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITGB3 P05106 7/20 0.48
▸ ITGA2B P08514 7/20 0.48
▸ CTSS P25774 3/20 0.47
▸ CTSK P43235 3/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ CPB1 P15086 1/20 0.42
▸ CPB2 Q96IY4 1/20 0.42
▸ CAPN1 P07384 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ SIRT6 Q8N6T7 1/20 0.41
▸ SIRT1 Q96EB6 1/20 0.41
▸ C3AR1 Q16581 1/20 0.41
▸ FOLH1 Q04609 1/20 0.40
▸ HDAC4 P56524 1/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ SIRT5 Q9NXA8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29758455 0.91 MEN1 (0.52) ITGB3ITGA2BCTSSCTSKMEN1
SCHEMBL29445600 0.91 MEN1 (0.52) ITGB3ITGA2BCTSSCTSKMEN1
SCHEMBL28799365 0.91 MEN1 (0.52) ITGB3ITGA2BCTSSCTSKMEN1
SCHEMBL29593510 0.90 CTSK (0.60) CTSSCTSKMEN1GAAKMT2A
SCHEMBL10190373 0.89 MEN1 (0.57) ITGB3ITGA2BCTSSCTSKMEN1
SCHEMBL16862524 0.89 MEN1 (0.57) ITGB3ITGA2BCTSSCTSKMEN1
SCHEMBL27771651 0.88 MEN1 (0.52) ITGB3ITGA2BCTSSCTSKMEN1
SCHEMBL31407660 0.88 MEN1 (0.52) ITGB3ITGA2BCTSSCTSKMEN1
SCHEMBL16351993 0.87 CAPN1 (0.53) ITGB3ITGA2BCTSSCTSKMEN1
SCHEMBL31389330 0.87 CTSS (0.53) ITGB3ITGA2BCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122028938-A Pharmaceutical combination comprising an anti-CD 37 antibody maytansinoid conjugate and a BCL2 inhibitor or PI3K inhibitor 德彪药业国际股份公司 2026-05-12 — — CN disclosed
US-20250249113-A1 LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES DEBIOPHARM RESEARCH & MANUFACTURING SA (CH) 2025-08-07 — — US disclosed
WO-2025083205-A1 DRUG COMBINATION COMPRISING ANTI-CD37 ANTIBODY MAYTANSINE CONJUGATE AND BCL2 INHIBITOR OR PI3K INHIBITOR DEBIOPHARM INTERNATIONAL S.A. (CH) 2025-04-24 — — WO disclosed
EP-4507734-A1 LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES Debiopharm Research & Manufacturing S.A. (CH) 2025-02-19 — — EP disclosed
CN-119255824-A Ligand-drug conjugates with improved pharmacokinetic and drug release profiles 德比欧药物研究有限公司 2025-01-03 — — CN disclosed
WO-2023198884-A1 LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) 2023-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250249113-A1 LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES FCER2, FCGR2A, FCGR1A ITGB3 682/4885ITGA2B 779/4885CTSS 1628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.